Reis Henning, Völkl Lisa, Demes Melanie, Moinfar Farid, Wild Peter J
Dr. Senckenbergisches Institut für Pathologie (SIP), Universitätsklinikum Frankfurt, Goethe Universität Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt am Main, Deutschland.
Vinzenzpathologieverbund, Institut für klinische Pathologie und Molekularpathologie, Ordensklinikum Linz, Linz, Österreich.
Pathologie (Heidelb). 2023 Sep;44(5):320-328. doi: 10.1007/s00292-023-01214-4. Epub 2023 Aug 16.
Ovarian cancer is a common malignant genital neoplasm in women. Due to its frequent diagnosis only in advanced stages, prognosis is poor, although biomarker-driven targeted therapeutic approaches are evolving. These are currently based on molecular pathological analyses of homologous recombination deficiency (HRD) and the BRCA1/2 mutational status. The current CME article focuses on the histo- and molecular pathology of ovarian cancer, relevant molecular mechanisms, and test systems. These are discussed in the context of biomarker-driven targeted therapy.
卵巢癌是女性常见的恶性生殖系统肿瘤。由于其往往在晚期才被诊断出来，尽管基于生物标志物的靶向治疗方法不断发展，但其预后仍然很差。目前这些方法基于同源重组缺陷（HRD）和BRCA1/2突变状态的分子病理分析。当前这篇继续医学教育文章聚焦于卵巢癌的组织病理学和分子病理学、相关分子机制以及检测系统。这些将在生物标志物驱动的靶向治疗背景下进行讨论。
